Stock Market Reviews

NBIX (Neurocrine Biosciences, Inc.) News

Get the latest news, insights, and market updates on NBIX (Neurocrine Biosciences, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data
  This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.
  Feb 19, 2026 - $NBIX
• This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition
  This UK-based biotech advances clinical-stage therapies for rare diseases, targeting specialty care markets with a diversified pipeline.
  Feb 19, 2026 - $NBIX
• Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead
  Focused on retinal disease therapies, Kodiak Sciences leads with clinical-stage candidates targeting major unmet needs in ophthalmology.
  Feb 19, 2026 - $NBIX
• CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale
  This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients with limited treatment options.
  Feb 19, 2026 - $NBIX
• BrightSpring Stock Up 86% as Braidwell Takes $45 Million Stake in Healthcare Services Provider
  BrightSpring Health Services delivers integrated pharmacy and clinical care to Medicare, Medicaid, and insured patients nationwide.
  Feb 19, 2026 - $NBIX
• Needham Bullish on Neurocrine Biosciences, Inc. (NBIX) Pipeline Amid 2026 Growth Expectations for Crenessity and Ingrezza
  Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) takes second position on our list of most promising stocks. TheFly reported on February 12 that Needham lowered its price target on NBIX to $185 from $187 and maintained a Buy rating. The company is still hopeful about Crenessity’s growth in 2026 […]
  Feb 19, 2026 - $NBIX
• New Strong Sell Stocks for February 18th
  COIN, NBIX and UPST have been added to the Zacks Rank #5 (Strong Sell) List on February 18th, 2026.
  Feb 18, 2026 - $NBIX
• A Look At Neurocrine Biosciences (NBIX) Valuation After Strong 2025 Results And 2026 Guidance
  What the latest earnings mean for Neurocrine Biosciences stock Neurocrine Biosciences (NBIX) just posted fourth quarter and full year 2025 results, paired with fresh 2026 guidance. Together, these give you a clearer picture of how INGREZZA and CRENESSITY are driving the business. See our latest analysis for Neurocrine Biosciences. Despite strong 2025 earnings and detailed 2026 guidance, the share price has recently been under pressure, with a 7 day share price return of 12.10% and a 90 day...
  Feb 14, 2026 - $NBIX
• Neurocrine (NBIX) Q4 2025 Earnings Call Transcript
  As Neurocrine enters 2026, our foundation is stronger than at any point in our more than 30-year history and it continues to strengthen, with growing enterprise-wide momentum and strategic and balanced diversification, Neurocrine has entered a new era of meaningful growth led by our first and best-in-class commercial brands. INGREZZA performance continues to impress, strategic investments in access and sales force expansion drove a record year for both new and total prescriptions. This momentum carries us into 2026, where despite 9 years post launch, we expect double-digit volume-driven growth supported by continued demand from the roughly 9 out of 10 TD or HD chorea patients not currently taking a VMAT2 inhibitor.
  Feb 12, 2026 - $NBIX
• Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor
  Neurocrine and Alnylam each face investor questions about the growth potential of key franchises. Ascendis, meanwhile, saw an upbeat sales report overshadowed by the progress of an emerging rival.
  Feb 12, 2026 - $NBIX